NCT00022477已完成2 期
A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 15
- 主要终点
- Response rate of BMS-247550 in colon cancer
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or metastatic colorectal cancer.
详细描述
OBJECTIVES:
- Determine the objective response rate in patients with locally recurrent or metastatic colorectal cancer treated with BMS-247550.
- Determine the toxicity of this drug in these patients.
- Determine the duration of response, median and overall survival, and time to progression in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
BMS-247550
Experimental
IV administration of BMS-247550 once every 21 days
干预措施: BMS-247550 (Drug)
结局指标
主要结局
Response rate of BMS-247550 in colon cancer
时间窗: 6 weeks
次要结局
未报告次要终点
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
BMS-247550 in Treating Women With Metastatic Breast CancerBreast CancerNCT00020904Memorial Sloan Kettering Cancer Center
终止
2 期
BMS-247550 in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00033306University of Alabama at Birmingham2
已完成
2 期
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With ChemotherapyGastric CancerEsophageal CancerNCT00017056Memorial Sloan Kettering Cancer Center
已完成
2 期
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With ChemotherapyGastric CancerEsophageal CancerNCT00017043Bristol-Myers Squibb
已完成
2 期
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00016393SWOG Cancer Research Network